巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Cellectar Biosciences

    CLRB
    3.420
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Cellectar Biosciences - 延遲價格・最後更新於 30/09 8:28
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    3.420
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    2.740
    賣出
    4.880
    每手股數
    --
    市值(百萬)
    20.90
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    10.300 - 3.350
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Cellectar Biosciences
    證券代碼
    CLRB.US
    所屬板塊
    Biotechnology
    公司業務
    Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
    發行量
    6110125
    公司總部
    100 Campus Drive
    公司網址
    https://www.cellectar.com
    公司電郵
    epiros@rodmanandrenshaw.com
    公司電話
    +1 608 441-8120
    暫無內容

    關於

    Cellectar Biosciences(CLRB.US)所屬的行業板塊為Biotechnology。
    Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
    詳細公司背景可參考: https://www.cellectar.com